

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number
WO 2005/047335 A1

(51) International Patent Classification⁷: **C07K 19/00, 16/46**

(21) International Application Number: **PCT/KR2004/002943**

(22) International Filing Date: **13 November 2004 (13.11.2004)**

(25) Filing Language: **Korean**

(26) Publication Language: **English**

(30) Priority Data:
10-2003-0080299
13 November 2003 (13.11.2003) KR

(71) Applicant (*for all designated States except US*): **HANMI PHARM. IND. LTD. [KR/KR]; #893-5, Hajeo-ri, Paltan-myeon, Hwaseong-si, Gyeonggi-do 445-813 (KR).**

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **JUNG, Sung, Youb**


[KR/KR]; #651-301, Miju Apt., Yeongtong-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-470 (KR). KIM, Jin, Sun [KR/KR]; #514-601, Ha-an Apt., Haan-dong, Gwangmyeong-si, Gyeonggi-do 423-060 (KR). PARK, Young, Jin [KR/KR]; #203-204, Jo-eun Villa, Mangpo-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-400 (KR). CHOI, Ki-Doo [KR/KR]; #801-702, Woosung Apt., Gaepo2-dong, Gangnam-gu, Seoul 135-242 (KR). KWON, Se, Chang [KR/KR]; #1002-2103, Hyundai 10-cha Apt., Gwangjang-dong, Gwangjin-gu, Seoul 143-210 (KR). LEE, Gwan, Sun [KR/KR]; #3-404, Woochang Apt., Ogeum-dong, Songpa-gu, Seoul 138-739 (KR).

(74) Agent: **SON, Min; 19th Floor, City Air Tower, 159-9 Sam-sung-dong, Gangnam-gu, Seoul 135-973 (KR).**

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH,**

[Continued on next page]

(54) Title: METHOD FOR THEMASS PRODUCTION OF IMMUNOGLOBULIN CONSTANT REGION



(57) Abstract: Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an *E. coli*-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.



PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.